Regeneron and Sanofi’s cholesterol-lowering drug study meets primary endpoint in phase 3 trial
Praluent is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor indicated as adjunct to diet and maximally tolerated statin therapy to treat adults with heterozygous familial hypercholesterolemia (HeFH)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.